| Position 2008 (2007) | Therapeutric category (code) | No of products 2008 (2007) |
|---|---|---|
| 1 (1) | Anticancer, other (K6Z) | 1373 (1158) |
| 2 (2) | Anticancer, immunological (K3) | 771 (618) |
| 3 (3) | Antidiabetic (A10B) | 503 (394) |
| 4 (4) | Analgesic, other (N2Z) | 450 (335) |
| 5 (5) | Prophylactic vaccine (J7A1) | 414 (332) |
| 6 (8) | Anti-inflammatory (M1A1) | 356 (268) |
| 7 (6) | Cardiovascular (C9Z) | 354 (325) |
| 8 (7) | Cognition enhancer (N6D) | 321 (307) |
| 9 (9) | GI inflammatory/bowel disorders (A16) | 313 (225) |
| 10 (10) | Antiasthma (R8A) | 313 (262) |
| 11 (12) | Antiviral, other (J5Z) | 302 (245) |
| 12 (13) | Ophthalmological (S1Z) | 299 (245) |
| 13 (11) | Recombinant vaccine (T2B) | 298 (251) |
| 14 (15) | Immunosuppressant (I5) | 289 (227) |
| 15 (19) | Formulation, fixed-dose combination (F9B) | 285 (197) |
| 16 (-) | Recombinant, other (T2Z) | 265 (-) |
| 17 (14) | Neuroprotective (N7C) Antiarthritic, other (M2Z) | 261 (230) |
| 18 (17) | Antiarthritic, other (M2Z) | 257 (201) |
| 19 (16) | Hypolipaemic/antiatherosclerosis (C10) | 239 (224) |
| 20 (25) | Monoclonal antibody, fully-human (T3A2) | 238 (184) |
| 21 (20) | Symptomatic antidiabetic (A10C) | 232 (191) |
| 22 (18) | Monoclonal antibody, other (T3A9) | 231 (201) |
| 23 (21) | Gene therapy (T4A) | 223 (191) |
| 24 (23) | Urological (G4Z) | 219 (188) |
| 25 (22) | Antiparkinsonian (N4A) | 215 (188) |
| Table 3: Top 25 therapeutic categories for R&D | ||